Clinical trials: COMBO Condition
COMBO Condition, STIGMA Condition
Effects of Internet-based Storytelling Programs in Reducing Mental Illness Stigma With Mediation by Interactivity and Stigma Content
Mental illness stigma has been a concerning issue globally due to its adverse effects on the recovery of people with mental illness and may delay help-seeking for mental health out of the concern of being stigmatized.
- Conditions
- COMBO Condition, STIGMA Condition, INTERACT Condition, CONTROL Condition
- Trial name
- NCT05333848
- Testing
- Internet-based storytelling programs with interactivity and stigma content, Internet-based storytelling programs with stigma content only, Internet-based storytelling programs with interactivity only
- Where
- Hong Kong
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Multiple Myeloma
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
- Trial name
- NCT00090493
- Testing
- MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Asthma
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Primary objective To show the superiority of CHF 1535 (BDP/FF) pMDI (800/24 μg per day) over BDP HFA pMDI (800 μg per day) in terms of change from baseline to the entire treatment period in average pre-dose morning peak…
- Trial name
- FORCE (NCT01577082)
- Testing
- CHF1535 200/6 µg pMDI, BDP HFA 100 µg pMDI
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 542 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Covid19
Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt
Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis.
- Trial name
- NCT04773756
- Testing
- Sofosbuvir 400 MG/ Daclatasvir 60mg
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Alexandria University
Hypoxia, Esophageal Cancer
COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. This is particularly true for obese patients, who have a higher incidence of hypoxia.
- Conditions
- Hypoxia, Esophageal Cancer, Colon Cancer, Gastric Cancer
- Trial name
- NCT06804876
- Testing
- the COMBO Endoscopy Oropharyngeal Airway
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Zhejiang University
Multiple Myeloma
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib (VELCADE) in combination with pralatrexate in patients with previously treated multiple myeloma, AL amyloid and Waldenstroem's…
- Trial name
- NCT01114282
- Testing
- velcade, Pralatrexate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Leukemia, Acute Myeloid Leukemia (AML)
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
The purpose of the trial is to study how the elderly patients who have previously undergone treatment for acute myeloid leukemia and high-rRisk myelodysplastic syndromes, respond to a combined treatment with azacitidine and…
- Conditions
- Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT01442714
- Testing
- Azacitidine, Lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Stanford University
Coronary Heart Disease, Angina Pectoris
SORT OUT X - Combo Stent Versus ORSIRO Stent
The aim of the Danish Organisation for randomised trials with clinical outcome (SORT OUT) is to compare the safety and efficacy of the ComboTM stent and Orsiro™ stent in the treatment of unselected patients with ischemic heart…
- Conditions
- Coronary Heart Disease, Angina Pectoris, Myocardial Infarction
- Trial name
- SORT OUT X (NCT03216733)
- Testing
- COMBO, ORSIRO
- Where
- 4 sites in Denmark
- Volunteers
- 3,148 people
- Sponsor
- Aarhus University Hospital Skejby
Non Hodgkin's Lymphoma
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
This is a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine in a combination with high-dose etoposide and cyclophosphamide.
- Trial name
- NCT00477945
- Testing
- clofarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
The objectives of this study are to establish the performance characteristics of the AC2 (APTIMA Combo 2) Assay on the PANTHER System for the sample types cleared for use on the TIGRIS and DTS (Direct Tube Sampling) Systems and…
- Trial name
- NCT01733069
- Testing
- APTIMA COMBO 2 Assay (AC2 Assay)
- Where
- 7 sites in United States
- Volunteers
- 1,912 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
HIV I Infection, HIV-2 Infection
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
The objective of this study is the collection and testing of clinical samples to determine the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access Immunoassay Analyzer
- Trial name
- HIV-EU-11-18 (NCT04971343)
- Testing
- Access HIV_blood donor, Access HIV_Hospitalized patient, Access HIV_known HIV-1 antibody positives
- Where
- 6 sites in France
- Volunteers
- 8,650 people
- Sponsor
- Beckman Coulter, Inc.
Influenza Type A, Influenza Type B
Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere
The study is designed as a clinical feasibility, to investigate the positive and negative percent agreement (PPA and NPA) of the BinaxNOW™ COVID-19/Flu A\&B Combo against a highly sensitive PCR method(s) in symptomatic patients…
- Conditions
- Influenza Type A, Influenza Type B, COVID-19
- Trial name
- NCT06928129
- Testing
- BinaxNOW™ COVID-19/Flu A&B Combo Self-Test
- Volunteers
- 700 people
- Sponsor
- Abbott Rapid Dx
Hypoxia, Esophageal Cancer
Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients
Hypoxia is the most common adverse event during propofol sedation for gastrointestinal endoscopy, particularly in obese patients.
- Conditions
- Hypoxia, Esophageal Cancer, Gastric Cancer, Polyp of Colon
- Trial name
- NCT06812403
- Testing
- the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Hypertension
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
- Trial name
- NCT00219180
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 1,797 people
- Sponsor
- Novartis
Complication,Postoperative
Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival
This randomized clinical trial aims to compare the effectiveness of heparin alone versus combination therapy of Heparin- Aspirin in improving free flap survival in patients undergoing reconstructive surgery.
- Trial name
- NCT06512233
- Testing
- LMW Heparin 5000 U/ML-Aspirin 75 MG, LMW Heparin 5000 U/ML
- Where
- Pakistan
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Hypoxemia, Esophageal Cancer
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent airway collapse.
- Conditions
- Hypoxemia, Esophageal Cancer, Morbidly Obese Patients, Gastric Cancer
- Trial name
- NCT07175155
- Testing
- COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation, High-Flow Nasal Cannula Oxygenation
- Where
- 5 sites in China
- Volunteers
- 410 people
- Sponsor
- Zhejiang University
Multiple Myeloma
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.
- Trial name
- NCT01355705
- Testing
- Amrubicin, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michaela Liedtke
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01644188
- Testing
- Alirocumab, Ezetimibe, Lipid Modifying Therapy (LMT)
- Where
- 126 sites in United States, Canada and 8 more
- Volunteers
- 720 people
- Sponsor
- Sanofi
Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice
COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) with propofol.
- Conditions
- Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
- Trial name
- NCT07012772
- Testing
- The COMBO Endoscopy Oropharyngeal Airway
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical…
- Trial name
- NCT07130695
- Testing
- Olutasidenib Investigational Agent Administration
- Sponsor
- Virginia Commonwealth University